[asbmr 2018年年会会议报告-骨质疏松症临床实践-]

Clinical calcium Pub Date : 2019-01-01 DOI:CliCa1901108111

Reiko Watanabe, Daisuke Inoue

{"title":"[asbmr 2018年年会会议报告-骨质疏松症临床实践-]","authors":"Reiko Watanabe, Daisuke Inoue","doi":"CliCa1901108111","DOIUrl":null,"url":null,"abstract":"In the 2018 ASBMR annual meeting, many important results were reported, showing the effects of anti-osteoporotic drugs already focusing on bone quality and the concept of \"treat-to-target\", although there were few big topics on novel drugs. However, some reports on new drugs, such as probiotics and SARM(selective androgen receptor modulator), did draw attention.","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 1","pages":"108-111"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[A meeting Report on the 2018 annual meeting of ASBMR-Clinical practice of the osteoporosis-.]\",\"authors\":\"Reiko Watanabe, Daisuke Inoue\",\"doi\":\"CliCa1901108111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the 2018 ASBMR annual meeting, many important results were reported, showing the effects of anti-osteoporotic drugs already focusing on bone quality and the concept of \\\"treat-to-target\\\", although there were few big topics on novel drugs. However, some reports on new drugs, such as probiotics and SARM(selective androgen receptor modulator), did draw attention.\",\"PeriodicalId\":10389,\"journal\":{\"name\":\"Clinical calcium\",\"volume\":\"29 1\",\"pages\":\"108-111\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical calcium\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/CliCa1901108111\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical calcium","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/CliCa1901108111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

在2018年ASBMR年会上，报告了许多重要的结果，表明抗骨质疏松药物的作用已经集中在骨质量和“治疗到目标”的概念上，尽管关于新药的大课题很少。然而，一些关于益生菌和选择性雄激素受体调节剂(SARM)等新药的报道引起了人们的注意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[A meeting Report on the 2018 annual meeting of ASBMR-Clinical practice of the osteoporosis-.]

In the 2018 ASBMR annual meeting, many important results were reported, showing the effects of anti-osteoporotic drugs already focusing on bone quality and the concept of "treat-to-target", although there were few big topics on novel drugs. However, some reports on new drugs, such as probiotics and SARM(selective androgen receptor modulator), did draw attention.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical calcium

自引率

0.00%

发文量